PSC 4215 - Exam 1 - Drug discovery and Approval

studied byStudied by 0 people
0.0(0)
learn
LearnA personalized and smart learning plan
exam
Practice TestTake a test on your terms and definitions
spaced repetition
Spaced RepetitionScientifically backed study method
heart puzzle
Matching GameHow quick can you match all your cards?
flashcards
FlashcardsStudy terms and definitions

1 / 18

encourage image

There's no tags or description

Looks like no one added any tags here yet for you.

19 Terms

1

Where can leads for new drugs come from? (6)

  1. Competitor compounds

  2. Endogenous ligands

  3. Random screening/compound file

  4. Natural products

  5. Scientific literature

  6. Combinatorial libraries/AI

New cards
2

Up to 5000 compounds screened to find _____ marketable drug

1

New cards
3

10,000 initial compounds → _____ make it to in vivo testing

10

New cards
4

Only _____ out of 12 development candidates becomes a marketed drug

1

New cards
5

Drug approval trends (1995-2004) show _____ recent trends

Upward

New cards
6

How long can drug discovery take?

1 to 5 years

New cards
7

What kind of information should be included in preclinical submissions?

  • Everything from start to finish

    • Drug info (structure, metabolism, toxicity, contraindications, overdose treatments, etc)

    • Objective, methods, manufacturing, investigators, institutions

    • etc.

New cards
8

T/F: Preclinical studies involve in vitro human testing on healthy patients

F, preclinical studies do NOT involve humans.

New cards
9

T/F: A drug that is in preclinical studies is an investigational drug that needs FDA approval before in vitro studies begin

F, drugs in preclinical studies is NOT considered an investigational drug until the preclinical studies are DONE and the FDA has approved it

New cards
10

When is the first time an investigational drug is given to patients

Phase 2 (Phase 1 = healthy humans, to record baseline effect)

New cards
11

If phase 3 studies suggest that the drug is effective, what must be file?

New Drug Submission/Application

New cards
12

Assess mechanism of action (MOA), toxicity, metabolism, and drug properties in lab and animal models. Submit findings to the FDA for investigational drug approval.

Pre clinical studies which takes 1.5 years

New cards
13

First human trials in healthy volunteers to establish dose-response curves and pharmacokinetics.

Phase 1 which takes 0.5 to 2 years

New cards
14

Small-scale trials in patients to evaluate elimination, metabolism, therapeutic benefits, dose ranges, and efficacy.

Phase 2 which takes 1 to 3 years

New cards
15

Large, randomized, double-blind clinical trials to confirm safety and effectiveness. Results support a New Drug Application (NDA) submission for FDA approval.

Phase 3 which takes 3 to 5 years

New cards
16

The FDA evaluates all data before granting marketing approval.

NDA Review which takes 1–2 years

New cards
17

(Post-Marketing Surveillance) – The drug is marketed and monitored worldwide for long-term safety, rare side effects, and dosing adjustments.

Phase 4

New cards
18

Summarize all of the phases of the drug approval process

  1. Preclinical Studies (1.5 years) – Assess mechanism of action (MOA), toxicity, metabolism, and drug properties in lab and animal models. Submit findings to the FDA for investigational drug approval.

  2. Phase 1 (0.5–2 years) – First human trials in healthy volunteers to establish dose-response curves and pharmacokinetics.

  3. Phase 2 (1–3 years) – Small-scale trials in patients to evaluate elimination, metabolism, therapeutic benefits, dose ranges, and efficacy.

  4. Phase 3 (3–5 years)Large, randomized, double-blind clinical trials to confirm safety and effectiveness. Results support a New Drug Application (NDA) submission for FDA approval.

  5. NDA Review (1–2 years) – The FDA evaluates all data before granting marketing approval.

  6. Phase 4 (Post-Marketing Surveillance) – The drug is marketed and monitored worldwide for long-term safety, rare side effects, and dosing adjustments.

The drug remains in new drug status until the FDA is confident in its safety and efficacy, at which point routine monitoring decreases.

New cards
19

T/F: While phase 1 is generally used to determine whether a drug is safe in humans, phase 2 is used to identify whether it works

T

New cards

Explore top notes

note Note
studied byStudied by 98 people
693 days ago
5.0(4)
note Note
studied byStudied by 241 people
678 days ago
5.0(2)
note Note
studied byStudied by 13 people
833 days ago
5.0(1)
note Note
studied byStudied by 52 people
787 days ago
5.0(1)
note Note
studied byStudied by 33 people
425 days ago
5.0(1)
note Note
studied byStudied by 9 people
169 days ago
5.0(2)
note Note
studied byStudied by 41 people
709 days ago
5.0(1)
note Note
studied byStudied by 100 people
760 days ago
5.0(2)

Explore top flashcards

flashcards Flashcard (112)
studied byStudied by 55 people
302 days ago
5.0(2)
flashcards Flashcard (198)
studied byStudied by 1 person
182 days ago
5.0(1)
flashcards Flashcard (24)
studied byStudied by 34 people
759 days ago
5.0(1)
flashcards Flashcard (47)
studied byStudied by 1 person
39 days ago
5.0(1)
flashcards Flashcard (137)
studied byStudied by 301 people
567 days ago
4.5(4)
flashcards Flashcard (308)
studied byStudied by 7 people
832 days ago
5.0(1)
flashcards Flashcard (35)
studied byStudied by 2 people
303 days ago
5.0(1)
flashcards Flashcard (334)
studied byStudied by 88 people
23 days ago
5.0(2)
robot